Crispina Calsada's most recent trade in Regulus Therapeutics Inc was a trade of 562,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 562,500 | 562,500 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 13 Jan 2025 | 38,716 | 50,566 (0%) | 0% | 1.3 | 48,906 | Common Stock |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 13 Jan 2025 | 5,088 | 45,478 (0%) | 0% | 1.3 | 6,427 | Common Stock |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.36 per share. | 09 Jan 2025 | 62,500 | 68,282 (0%) | 0% | 1.4 | 85,000 | Common Stock |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.30 per share. | 09 Jan 2025 | 21,000 | 89,282 (0%) | 0% | 1.3 | 27,300 | Common Stock |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 462,000 | 462,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.19 per share. | 18 Jan 2024 | 5,468 | 5,782 (0%) | 0% | 1.2 | 6,510 | Common Stock |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 11,250 | 11,250 (0%) | 0% | 0 | Common Stock | |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 375,000 | 375,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2023 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2022 | 480,000 | 480,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Crispina Calsada | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) |